Amicus Therapeutics (FOLD) posted fourth-quarter net loss attributable to common stockholders of $8.7 million, narrower than $10.0 million in the previous year period. Loss per share for the latest fourth quarter was $0.25, wider than $0.20 in the comparable quarter last year.
On average, seven analysts polled by Thomson Reuters expected the company to report a loss of $0.37 per share. Analysts' estimates typically exclude special items.
Total revenue for the latest quarter was $5.63 million. The company did not generate any revenue in the year-ago period.
For comments and feedback: editorial@rttnews.com